BioStar welcomes entrepreneurs and others to submit an executive summary or power point to rmasi@BioStarfund.com
We will then review the material and if interested, ask for a complete plan. We then would have management present to the Managing Members and Medical Venture Partners and Advisors. Although the due diligence process can take several months, we try extremely hard to work quickly and keep management apprised of where we are in the diligence process.
Please note that BioStar does not execute non-disclosure agreements. We also are unable to return copies of executive summaries or business plans.
General Investment Guidelines:
| Stage:
Security: Clinical Specialties: Clinical Requirements: Other: Size: Board Seat: Location: Technology: Other: |
Seed, first or second round of financing.
Typically convertible preferred stock Cardiovascular, gastroenterology, orthopedics, neurosciences, urological None. BioStar will invest in the design stage. Biomaterials $250,000 - $3 million in first round Yes, but not required Throughout the US The product must be based on strongly protected I/P. BioStar prefers to invest in those areas where it believes it can serve as a value-add investor in the clinical as well as business efforts of a company. |